Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) plans to acquire a 15% stake in its subsidiary Xin Nuoming Biopharmaceuticals.

Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) announced that its controlling subsidiary Xin Nuoming Biotechnology's minority shareholders, Fund I and Jingchuang Fund, plan to transfer their combined 15% equity stake in Xin Nuoming Biotechnology through a public transfer on the Southwest United Equity Exchange. The company plans to use self-raised funds not exceeding 5% above the listing base price and not exceeding RMB 45 million to competitively acquire Fund I and Jingchuang Fund's combined 15% equity stake in Xin Nuoming Biotechnology. This includes acquiring 8.1081% equity stake held by Fund I and 6.8919% equity stake held by Jingchuang Fund. After the completion of this equity acquisition, it will further enhance the control and management efficiency of the subsidiary, contributing to strengthening the overall strategic coordination and resource integration of the company.